Pyxis Oncology, Inc.
Qualité des données : 100%
PYXS
Nasdaq
Manufacturing
Chemicals
1,70 €
▲
0,09 €
(5,59%)
Cap. Boursière: 99,90 M
Prix
1,59 €
Cap. Boursière
99,90 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—
Quick Summary
Points Clés
Negative free cash flow of -63,51 M
Capital efficient — spends only 0,06% of revenue on capex
Croissance
Revenue Growth (5Y)
N/A
Revenue (1Y)-14,17%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Qualité
Return on Equity
-101,80%
En dessous de la moyenne du secteur (-53,47%)
ROIC-69,56%
Net Margin-574,55%
Op. Margin-609,18%
Sécurité
Debt / Equity
N/A
Current Ratio4,29
Interest CoverageN/A
Valorisation
PE (TTM)
-1,25
Au-dessus de la moyenne du secteur (-1,48)
P/B Ratio1,45
EV/EBITDAN/A
Dividend YieldN/A
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1364 pairs)
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1364 pairs)| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | -1,3 | -1,5 |
| P/B | 1,5 | 1,6 |
| ROE % | -101,8 | -53,5 |
| Net Margin % | -574,6 | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
Objectif de Cours des Analystes
8 analystes
Buy
Actuel
1,70 €
Objectif
6,88 €
5,00 €
7,00 €
9,00 €
Prévisions
P/E Prévisionnel
-1,31
BPA Prévisionnel
-1,30 €
CA Est.
3,13 M
Estimations de Bénéfices
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| FY2027 |
-1,30 €
-1,81 € – -0,85 €
|
3,13 M | 8 |
| FY2026 |
-1,28 €
-1,56 € – -0,95 €
|
43 750,0 | 8 |
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| 2026 Q2 |
-0,38 €
-0,43 € – -0,31 €
|
21 880,0 | 8 |
| 2026 Q1 |
-0,36 €
-0,42 € – -0,31 €
|
0,0 | 8 |
Surprises de Résultats
Derniers 4 trimestres
| Trimestre | BPA Est. | BPA Réel | Surprise |
|---|---|---|---|
| Q42025 | -0,34 € | -0,29 € | +14,4% |
| Q32025 | -0,34 € | -0,35 € | -3,4% |
| Q22025 | -0,35 € | -0,30 € | +14,7% |
| Q12025 | -0,30 € | -0,35 € | -16,7% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -14,17% | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 13,86 M | Net Income (TTM) | -79,62 M |
| ROE | -101,80% | ROA | -69,59% |
| Gross Margin | N/A | Operating Margin | -609,18% |
| Net Margin | -574,55% | Free Cash Flow (TTM) | -63,51 M |
| ROIC | -69,56% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 4,29 |
| Interest Coverage | N/A | Asset Turnover | 0,12 |
| Working Capital | 63,69 M | Tangible Book Value | 66,35 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1,25 | Forward P/E | N/A |
| P/B Ratio | 1,45 | P/S Ratio | 7,21 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -63,57% | ||
| Market Cap | 99,90 M | Enterprise Value | 90,98 M |
| Per Share | |||
| EPS (Diluted TTM) | -1,28 | Revenue / Share | 0,22 |
| FCF / Share | -1,01 | OCF / Share | -1,01 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 0,06% | FCF Conversion | 79,77% |
| SBC-Adj. FCF | -76,21 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 13,86 M | 16,15 M | — | — | — |
| Net Income | -79,62 M | -77,33 M | -73,79 M | -120,72 M | -75,98 M |
| EPS (Diluted) | -1,28 | -1,32 | -1,85 | -3,65 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -84,42 M | -89,46 M | -82,20 M | -123,48 M | -69,72 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 73,70 M | 58,75 M | 49,59 M | 86,13 M | 51,05 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 4,51 M | 2,98 M | 1,93 M | 709 000,0 | 647 000,0 |
| Interest Expense | — | — | — | — | — |
| Income Tax | 1,39 M | -2,16 M | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 91,52 M | 157,18 M | 173,73 M | 211,38 M | 280,02 M |
| Total Liabilities | 38,11 M | 36,43 M | 48,02 M | 50,56 M | 18,71 M |
| Shareholders' Equity | 53,41 M | 120,75 M | 125,70 M | 160,82 M | 261,31 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 15,42 M | 19,47 M | 9,66 M | 179,29 M | 274,74 M |
| Current Assets | 72,11 M | 132,44 M | 124,60 M | 186,61 M | 278,67 M |
| Current Liabilities | 21,13 M | 17,68 M | 25,76 M | 31,63 M | 18,71 M |
{"event":"ticker_viewed","properties":{"ticker":"PYXS","listing_kind":"stock","pathname":"/stocks/pyxs","exchange":"Nasdaq","country":"US"}}